Apoglyx is a pre-clinical stage biotech company with the aim to develop a small molecule therapy for sepsis, and further indications, based on inhibition of Aquaporin-9.
Apoglyx was founded based on research from Aarhus University (DK), Aalborg University (DK), and Lund University (S).
Apoglyx was founded based on research from Aarhus University (DK), Aalborg University (DK), and Lund University (S).
Location: Sweden, Scania, Lund
Employees: 1-10
Founded date: 2015